#Odefsey

Advocates claim Gilead and others unfairly limited competition for HIV combination pills.

Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.

This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

In a recent study, Edurant was better tolerated and less toxic and led to fewer discontinuations.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Increases may be designed to push patients to the company’s newer regimens.

The FDA has approved the single-tablet antiretroviral regimen Odefsey, which includes a new, safer version of tenofovir.